ENDORSED BY
.png)
IN PARTNERSHIP WITH
.png)
Day 1
THURSDAY, 9 SEPTEMBER 2027
All Day
Registration, Foyer, Ground Floor, CCD
Morning
Pre-Congress Workshops
15.00
Welcome Address
Modern Breast Cancer Management - Lessons Learned
Professor Michael J Kerin, President RCSI
15.15
Debate 1 In the era of personalised medicine is traditional breast cancer trial design still relevant?
SESSION 1 - COMBINED SESSION
Debate 2 TBC
16.55
Break and visit the exhibition
17.30
17.20
Introduction of keynote
Keynote Lecture
Increasing Role of Circulating Tumor DNA in Breast Care Management
18.50
Welcome Reception
Day 2
FRIDAY, 10 SEPTEMBER 2027
07.30-08.30
Morning Symposia
08.30 - 10.00
SESSION 2 - PARALLEL SESSION
Parallel: Breast Pathology for
the Surgeon
Subtype of Triple Negative breast cancer - a more personalised approach to therapy
TBC
TBC
SESSION 2 - PARALLEL SESSION
Parallel: Emerging Therapy Strategies in ER + HER – Breast Cancer
Med Onc – Emerging Strategies in ER+ HER- breast cancer premenopausal
Should all new patients with ER+ disease be offered oral SERDs?
Should all patients with intermediate risk ER+ HER- breast cancer receive adjuvant CDK inhibitors?
Should all young women receive
ovarian suppression as part of
treatment for breast cancer?
10.00-10.30
Break and visit the exhibition
10.30 - 12.15
SESSION 3 - PARALLEL SESSION
Parallel: Management of the Axilla
ALND and TAD in the primary surgery setting – What is the evidence?
ALND is necessary after NACT in
node positive patients?
Omission of Sentinel Node Biopsy in Early Breast Cancer Yes or No?
SESSION 3 - PARALLEL SESSION
Parallel: Systemic Therapy
Does Anthracycline have a place in the treatment of ER +, HER-2 negative breast cancer?
Are new therapies replacing traditional regimes for ER+ disease?
Should all ER+, HER-2 negative receive immunotherapy?
12.15 - 13.15
Lunch and visit the exhibition
13.15 - 14.15
SESSION 4 - COMBINED SESSION
Top Papers of 2026 and 2027: An Overview of What is New
Surgical 30 minutes and Medical Oncology 30 minutes
16.15-18.00
SESSION 5 - PARALLEL SESSION
Parallel: DCIS
Radiotherapy is no longer the
standard of care for DCIS
Is Surgery required for all DCIS?
Decision making algorithms for
adjuvant therapies DCIS
SESSION 5 - PARALLEL SESSION
Parallel: Management of HER-2
Low Disease
HER-2 low cancer is a misclassification and has no therapeutic strategy
Defining HER-2 low disease pathology
Drugs sequencing in HER-2 low
breast cancer
15.45 - 16.15
Break and visit the exhibition
16.15-18.00
SESSION 6 - PARALLEL SESSION
Parallel: Innovation
All patients being offered a
mastectomy should have access to a robotic procedure. Yes or No?
Breast Conserving Surgery for
Multifocal Disease Yes or No?
Role of Lymphodema Surgery in
Breast Cancer Patients
SESSION 6 - PARALLEL SESSION
Parallel: Metastatic Disease
Should all patients with metastatic breast cancer undergo somatic gene analysis?
Treatment beyond CDK inhibition in ER+ metastatic breast cancer?
Drug sequencing in metastatic HER2 positive breast cancer
Should all young women receive
ovarian suppression as part of
treatment for breast cancer?
Day 3
SATURDAY, 11 SEPTEMBER 2027
07.30-08.30
Morning Symposia
08.30-09.30
SESSION 7 - PLENARY SESSION
(Oral presentations from submitted abstracts)
09.30-10.30
SESSION 8 - PARALLEL SESSION
Parallel: Update on Surgical Trials
TBC
SESSION 8 - PARALLEL SESSION
Parallel: Survivorship
Pregnancy after breast cancer, is it safe?
The role of HRT after breast cancer
Risk Modification
10.30-11.00
Break and visit the exhibition
11.00 - 12.45
SESSION 9 - COMBINED SESSION
Lobular Breast Cancer
TBC
TBC
TBC
TBC
12.45-13.45
Lunch and visit the exhibition
13.45 - 15.30
SESSION 10 - COMBINED SESSION
Genetics and High Risk Screening
- AI/Risk Prediction
- Update on Prediction Models
Debate 1 - Should all patients with breast cancer have routine germline genetic panel testing?
Debate 2 - All patients with high risk penetrance genes should be offered Breast Conserving Therapy?
15.30
Close of Congress